Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7641621 | 0.86 | ALDH1A1 (0.52) | KMT2APOLBALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL19308459 | 0.85 | NAMPT (0.47) | NAMPTCYP19A1CYP17A1KDM4EKMT2A | |
| SCHEMBL28997377 | 0.84 | POLB (0.53) | NAMPTCYP19A1CYP17A1KDM4EKMT2A | |
| SCHEMBL27809176 | 0.84 | NAMPT (0.56) | NAMPTCYP19A1CYP17A1KDM4EKMT2A | |
| SCHEMBL14062590 | 0.83 | CYP19A1 (0.46) | NAMPTCYP19A1CYP17A1KDM4EKMT2A | |
| SCHEMBL9867427 | 0.81 | POLB (0.47) | NAMPTCYP19A1CYP17A1KDM4EKMT2A | |
| SCHEMBL23049788 | 0.81 | CYP19A1 (0.47) | NAMPTCYP19A1CYP17A1KDM4EKMT2A | |
| SCHEMBL18087031 | 0.80 | ALDH1A1 (0.47) | KMT2AALDH1A1L3MBTL1MAPK1MAPT | |
| SCHEMBL126010 | 0.80 | KMT2A (0.57) | KMT2AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL2623828 | 0.80 | RXRA (0.47) | KDM4EKMT2APOLBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| WO-2020133091-A1 | PYRIDYLOXY CARBOXYLATE DERIVATIVE, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | disclosed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| CN-1133625-C | Quinazoline derivatives | — | 2004-01-07 | — | — | CN | disclosed |
| CN-1114591-C | cyclic amide compound | KOWA CO (JP) | 2003-07-16 | — | — | CN | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1291186-A | Cyclic amide compounds | KOWA CO (JP) | 2001-04-11 | — | — | CN | disclosed |
| CN-1205694-A | Quinazoline derivatives | ZENECA LTD (GB) | 1999-01-20 | — | — | CN | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | NAMPT 2727/4885CYP19A1 1256/4885CYP17A1 2178/4885 |
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | NAMPT 1619/4885CYP19A1 615/4885CYP17A1 284/4885 |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | NAMPT 498/4885CYP19A1 1467/4885CYP17A1 908/4885 |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | WEE1, CBR3, GLRX3 | NAMPT 990/4885CYP19A1 848/4885CYP17A1 656/4885 |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | PHGDH, G6PD, PHPT1 | NAMPT 2727/4885CYP19A1 1256/4885CYP17A1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.